Science Moderna and Merck’s Personalized mRNA Melanoma Vaccine Meets Primary Endpoints in Landmark Phase 3 Trial August 20, 2026 Moderna and Merck announced on August 19 that a phase 3 trial of their experimental personalized mRNA cancer therapy, intismeran, in combination with Keytruda (pembrolizumab), met two key endpoints in…
Markets Moderna Rockets 93% and Merck Jumps 7% as Melanoma Therapy Meets Phase 3 Goal August 19, 2026 Moderna and Merck Deliver Historic Breakthrough in Cancer Treatment Shares of Moderna rocketed 93% to $121.76 in early Wednesday trading after the biotech company and partner Merck announced that their…
Health Replimune Resubmits Melanoma Drug After FDA Leadership Exodus May 29, 2026 Third Submission Follows Major Regulatory Changes Replimune Group will resubmit its biologics license application for melanoma therapy RP1 in the coming days. Replimune made the decision after significant leadership changes…